Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 51

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 51
---
#### Deliver on

#### the Pipeline
◦ In the first quarter of 2024, we announced that the FDA cleared our IND for ARV-393 and in the second quarter of 2024 announced that we had initiated a first-in-human Phase 1 clinical trial in the second quarter of 2024. However, our goal had not yet been completed by year end.

◦ We initiated the first-in-human SAD cohort of the Phase 1 clinical trial for ARV-102 in healthy volunteers in the first quarter of 2024, and we completed enrollment in the SAD portion of the Phase 1 clinical trial of ARV-102 in healthy volunteers at the Centre for Human Drug Research in Leiden, the Netherlands in the third quarter of 2024.

◦ In the second quarter of 2024, we received health authority approval to initiate the multiple ascending dose, or MAD, portion of the ongoing Phase 1 clinical trial of ARV-102 in healthy volunteers, and we initiated the MAD portion of this clinical trial in the third quarter of 2024.

◦ In the fourth quarter of 2024, we initiated dosing of the first patients with Parkinson’s disease in the SAD portion of the Phase 1 clinical trial of ARV-102.

◦ We advanced IND-enabling activities for our KRAS G12D degrader.

◦ We exceeded our clinical candidate nomination goal and achieved our lead optimization goal.

#### •

#### Achieve Corporate Objectives
◦ Under the terms of and as consideration for entering into the Transaction, Novartis paid to us one-time, upfront payment in the aggregate amount of $150.0 million. Under the License Agreement, we are also eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory, and commercial milestones for ARV-766 being met, as well as tiered royalties based upon worldwide net sales of ARV-766, subject to reduction under certain circumstances as provided in the License Agreement.

◦ In addition to the Transaction, we achieved additional cost savings through headcount changes, operational savings, and contract negotiations.

<div align='center'>37</div>

The following table presents the annual cash bonuses for each of our named executive officers for 2024 , as approved by our board of directors and compensation committee, as applicable, which were based on the 104.0% achievement of our previously-established corporate goals, as described above.

| Name                        |     |